Alzheimer’s - The Puzzle, The Partners, The Path Forward

A Discussion about Challenges and Opportunities in Pre-Competitive Partnerships, Clinical Trial Enrollment and Public Policy

 

View the archived videos from the Alzheimer's forum. Continue the conversation using the event hashtag #ALZpov.

 

Alzheimer's Report

Download the just released 2013 PhRMA Report: Medicines in Development for Alzheimer's Disease

 

Alzheimer's ReportDownload the report Researching Alzheimer's Medicines: Setbacks and Stepping Stones

 

 

 

 

Bio thumbnailView the speaker bios

 

 

 

 

Alzheimer’s Disease (AD) is a debilitating neurodegenerative disease that currently afflicts more than 5 million people in the U.S. In an effort to catalyze progress in AD innovation and R&D, PhRMA, in partnership with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation, is hosting an all-day forum to convene top industry and academic scientists, patients, policymakers, and other stakeholders. Key topics of focus will include how to accelerate the impact of pre-competitive collaborative efforts and exploring challenges in clinical trials recruitment unique to Alzheimer’s.

October 23, 2013
9am - 5:45pm
The National Academy of Sciences Building
2101 Constitution Ave., N.W.

Agenda:

  • Opening Remarks

Bill Chin, MD, Executive Vice President, Scientific & Regulatory Affairs, PhRMA

Tim Garnett, MD, Chief Medical Officer and Senior Vice President, Development Center of Excellence, Eli Lilly

 

  • Keynote Address

Permanent Present Tense: The Unforgettable Life of the Amnesic Patient, H.M.  

Suzanne Corkin, PhD, Professor of Behavioral Neuroscience, Emerita, Massachusetts Institute of Technology

 

  • Pre-Competitive Partnerships

To maximize collaborate efforts that would progress Alzheimer’s disease R&D, there is a need to examine public-private partnerships in the pre-competitive space. This panel will explore research areas presenting the greatest opportunities for future collaborations.

Moderator: Paul Aisen, MD, Director, Alzheimer’s Disease Cooperative Study Professor, Department of Neurosciences, UCSD
Stevin Zorn, PhD, Executive Vice President Research & Development, Lundbeck
Diane Stephenson, PhD, Executive Director, Coalition Against Major Diseases, C-Path
Howard Fillit, MD, Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation
Neil Buckholtz, Director, Division of Neuroscience, National Institute on Aging, NIH
David Wholley, Director, The Biomarkers Consortium, Foundation for the National Institutes of Health

 

  • Lunch

Stories from the Frontlines - Sponsored by the Alzheimer’s Association

 

  • Pre-Symptomatic Clinical Trials

There are several significant challenges in the clinical development of AD therapeutics, particularly as the focus shifts to earlier stages of the disease. This panel will discuss important discoveries that helped elucidate the clinical heterogeneity of the disease and the subsequent challenges in the use and adoption of clinical and functional endpoints in new clinical trial design.

Moderator: Alice Park, Health and medicine writer, TIME
Andrew Satlin, MD, Executive Vice President, Eisai
Nicholas Kozauer, MD, Clinical Team Leader, Division of Neurology Products, FDA
Paul Aisen, MD, Director, Alzheimer’s Disease Cooperative Study Professor, Department of Neurosciences, UCSD
Reed Tuckson, MD, Managing Director, Tuckson Health Connections and Former EVP and Chief of Medical Affairs, UnitedHealth Group
Neill Graff-Radford, MD, Neurologist, Mayo Clinic
Heather Snyder, PhD, Director of Medical and Scientific Operations, Alzheimer’s Association

 

  • Alzheimer’s: The Path to 2025

George Vradenburg, JD, Convener of Global CEO initiative on Alzheimer’s and Chairman and Co-Founder, USAgainstAlzheimer’s

 

  • The Path Forward for Science and Policy

Robert Egge, Vice President Policy, Alzheimer’s Association
Howard Fillit, MD, Executive Director and Chief Science Officer, Alzheimer’s Drug Discovery Foundation

 

  • Concluding Remarks

Bill Chin, MD, Executive Vice President, Scientific & Regulatory Affairs, PhRMA

 

View the full meeting agenda here.

Learn about the event sponsors by clicking on their logo:

Alzheimer's Association Logo

 

 

 

 

Alzheimer's Drug Discovery Foundation

 

 

 

 

 

PhRMA Logo

 

 

 

 

More On PhRMA — powered by PhRMApedia